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Abstract
Individuals with chronic kidney disease have elevated levels of oxidative stress and are at
a significantly higher risk of skeletal fracture. Advanced glycation end products (AGEs),
which accumulate in bone and compromise mechanical properties, are known to be driven
in part by oxidative stress. The goal of this study was to study effects of N-acetylcysteine
(NAC) on reducing oxidative stress and improving various bone parameters, most specifi-
cally mechanical properties, in an animal model of progressive CKD. Male Cy/+ (CKD) rats
and unaffected littermates were untreated (controls) or treated with NAC (80 mg/kg, IP)
from 30 to 35 weeks of age. Endpoint measures included serum biochemistries, assess-
ments of systemic oxidative stress, bone morphology, and mechanical properties, and AGE
levels in the bone. CKD rats had the expected phenotype that included low kidney function,
elevated parathyroid hormone, higher cortical porosity, and compromised mechanical prop-
erties. NAC treatment had mixed effects on oxidative stress markers, significantly reducing
TBARS (a measure of lipid peroxidation) while not affecting 8-OHdG (a marker of DNA oxi-
dation) levels. AGE levels in the bone were elevated in CKD animals and were reduced with
NAC although this did not translate to a benefit in bone mechanical properties. In conclusion,
NAC failed to significantly improve bone architecture/geometry/mechanical properties in our
rat model of progressive CKD.
Introduction
Ten percent of Americans suffer from chronic kidney disease (CKD) [1]. Individuals with
CKD are at a significantly higher risk of skeletal fracture and associated death, compared to
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the normal population [2]. The pathophysiology underling skeletal-related phenotype develop-
ment in CKD is complex and driven primarily through disturbances in bone and mineral
metabolism [3]. Yet there is a growing appreciation for factors outside of mineral metabolism
that contribute to skeletal fragility in CKD [4][5].
Advanced glycation end products (AGEs) represent a heterogeneous group of modified
proteins and fat that derive from the addition of a carbohydrate to an amino acid or lipid in a
non-enzymatic reaction involving sugar. AGE accumulation in the body is influenced by vari-
ous factors including levels of blood glucose (such as in diabetes), levels of dietary AGE intake,
and as both downstream and upstream consequences of increased oxidative stress [6]. Bone
represents the largest collection of long-lived proteins in the body, principally collagen, and
thus is highly susceptible to AGE accumulation [7]. In vitro [8][9,10], preclinical [11,12], and
clinical studies [13] have associated AGE accumulation/collagen cross-linking with reduced
bone mechanical properties.
In patients with CKD, regardless of the presence or absence of diabetes, there are increased
circulating levels of AGE proteins compared to age-matched controls [14,15]. We and others
have found increased skeletal AGE levels in CKD animal models, and we have shown these lev-
els are independent of PTH levels and bone turnover [12][16]. Thus AGE accumulation in
bone of patients with CKD may contribute to the poor fracture resistance similar to the reduc-
tion in mechanical properties that we have observed in our animal model of CKD [17–19] and
impaired bone quality in humans with this disease [20][21][22][23].
The anti-oxidant N-acetylcysteine (NAC) is commonly used in CKD as it has been shown
to reduce systemic oxidative stress and AGE formation [24][25]. Whether this translates to
reduced levels of AGEs in bone and, most importantly, improved mechanical properties, is
unclear. Therefore, the goal of this study was to test the hypothesis that NAC reduces oxidative




Cy/+ rats are characterized by an autosomal dominant mutation in Anks6, a gene that codes
for the protein SamCystin, and which has been linked to nephronophthisis in humans [26]. In
this rat model, the mutation leads to a slow and gradual onset of CKD, paralleling human
CKD conditions through the gradual development hyperphosphatemia, hyperparathyroidism,
and skeletal abnormalities [27,28].
Male Cy/+ (CKD) rats (n = 25) and unaffected normal littermates (NL; n = 18) were placed
on a casein diet (Envigo TD.04539; 0.7% Pi, 0.7% Ca, 15.9% Protein, 5.2% Fat) at 24 weeks of
age in order to produce a more consistent kidney disease phenotype [29]. A higher number of
CKD animals were started in the study due historical variability in disease and response to
treatment. At 30 weeks of age, a subset of CKD (n = 12) and NL (n = 9) rats began treatment
with N-acetylcysteine (NAC, 80 mg/kg, IP) for 5 weeks while the remaining animals served as
non-treated controls (without vehicle treatment). The 5-week treatment duration was chosen
as we have previously shown it to result in dramatic changes to bone properties in this model
[18,30]. The NAC dose was based upon previous studies [31][32] and pilot dosing studies in
our lab.
At 35 weeks of age, animals were anesthetized with isoflurane and underwent cardiac punc-
ture for blood collection followed by exsanguination and bilateral pneumothorax to ensure
death. Tibiae were fixed in 10% neutral buffered formalin and femora were stored in PBS-
soaked gauze and frozen at -20C for analysis. All procedures were approved by and carried out
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according to the rules and regulations of the Indiana University School of Medicine’s Institu-
tional Animal Care and Use Committee.
Biochemistry
Blood plasma was analyzed for BUN, calcium, and phosphorus using colorimetric assays
(Point Scientific, Canton, MI, or Sigma kits). Intact PTH was determined by ELISA (Alpco,
Salem, NH). Serum levels of an oxidative stress marker, 8-hydroxy-2’ -deoxyguanosine
(8-OHdG) were measured using an ELISA kit (Enzo Life Sciences, Farmingdale, NY) and
TBARS were measured using TBARS assay (TCA method) kit (Cayman Chemical, Ann Arbor,
MI).
Micro-Computed Tomography (microCT)
Proximal tibia were scanned with microCT (Skyscan 1172) using a 12 micron isotropic voxel
size for determination of trabecular bone volume (BV/TV, %) and cortical porosity, using
methods previously published [18]. BV/TV was measured within a region of interest in the
proximal metaphysis starting at ~0.5 mm below the most distal region of the growth plate and
extending downward for 1 mm. The ROI was manually drawn to excluded cortical bone. Cor-
tical porosity was assessed on a single slice at the most distal edge of the trabecular ROI with
the isolation of the cortex achieved through manual segmentation. Whole femur were scanned
(Skyscan 1176) at a nominal resolution of 18 microns to assess geometric properties including
total tissue area (TA), bone area (BA), polar cross-sectional moment of inertia (CSMIp) and
cortical thickness (Ct.Th) on a single slice located at 50% of bone length [33]. Scans and analy-
ses were done in accordance with standard guidelines [34].
Whole bone mechanics
Structural mechanical properties of the left femur were determined by four-point bending as
previously described [35]. The anterior surface was placed on two lower supports located ±9
mm from the mid-diaphysis (18 mm span length) with an upper span length of 6 mm. Speci-
mens were loaded to failure at a rate of 2 mm/min, producing a force-displacement curve for
each sample. Structural-dependent mechanical properties were obtained directly from these
curves, while apparent material properties were derived from the force-displacement curves,
CSMIp from microCT, and the distances from the centroid to the tensile surface using stan-
dard beam-bending equations for four-point bending [36].
Measurements of skeletal collagen cross-linking of femoral cortical bone
After mechanical testing, segments of the femoral cortex (~3 mm in length) were processed for
assessment of enzymatic collagen crosslinks and an AGE crosslink (pentosidine) by a high per-
formance liquid chromatography (HPLC) system (Beckman-Coulter System Gold 168) as pre-
viously published [12,37,38]. Briefly, the femoral shaft was flushed with saline to remove
marrow followed by incubating with Immunocal (Decal Chemical Corporation, Congers, NY)
to demineralize the bone for 2–3 days. Demineralization end-point determination assays
(Polysciences, Warrington, PA) were used to verify demineralization of each specimen. The
demineralized bone tissues were then hydrolyzed in 6 M HCL at 110˚C for 16 hours. Standards
of pyridinoline (PYD; Quidel), deoxypyridinoline (DPD; Quidel), and pentosidine (PE; Inter-
national Maillard Reaction Society) were used. Hydroxyproline levels, also measured by
HPLC, were used to normalize crosslink concentration (mol/mol collagen).
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Measurement of total AGEs in bone tissue
The same demineralized bone tissues that were hydrolyzed for enzymatic cross-links were
assessed for total AGE content using previously published methods [10,39]. Briefly, fluores-
cence readings taken with a CLARIOstar high performance microplate reader (BMG LAB-
TECH Inc, Cary, NC) at wavelengths of 370nm/440nm excitation/emission against a quinine
sulfate standard and normalized by the collagen content for the sample. The amount of colla-
gen for each bone specimen was based on the amount of hydroxyproline determined by a
hydroxyproline assay kit according to manufactures’ instruction (Sigma-Aldrich USA,
St. Louis, MO).
Statistics
Comparisons among groups were assessed by two-way ANOVA with the main effects being
disease (NL and CKD) and treatment (control vs. NAC). When a significant interaction was
found in the two-way ANOVA Fisher’s LSD post-hoc tests across all four groups were per-
formed. A priori α-levels were set at 0.05 to determine statistical significance. Data are pre-
sented as mean ± standard deviation.
Results
The effect of NAC on kidney function, mineral metabolism and oxidative
stress in CKD rats
CKD animals had significantly higher BUN (4-fold), phosphorus (1.7-fold) and serum PTH
(8-fold) compared to NL (Table 1). NAC did not reduce PTH or BUN but did result in signifi-
cantly lower phosphorus and significantly higher calcium in in CKD animals. There was no
difference in levels of serum oxidative stress markers 8-OHdG (Fig 1A) or TBARS (Fig 1B)
between NL and CKD rats. NAC had no effect on levels of 8-OHdG but decreased levels of
TBARS (Fig 1A & 1B).
The effect of NAC on skeletal morphology of femoral mid-diaphysis in
CKD rats
There was no significant effect of phenotype, treatment, or an interaction on proximal tibia
trabecular BV/TV (Fig 2A). Cortical porosity showed a significant main effect of phenotype
(higher in CKD), but it was not affected by treatment (Fig 2B). At the mid-diaphysis, bone
area, cross-sectional moment of inertia, and cortical thickness were all significantly affected by
genotype (lower in CKD) without being significantly affected by NAC. Only CKD animals had
Table 1. Systemic biochemical markers.







NAC (n = 9) Control (n = 13) NAC (n = 12)
Calcium, mg/dL 6.8 ± 1.2 7.3 ± 1.2 5.6 ± 1.9 8.0 ± 1.7 � 0.628 0.004 0.048
Phosphorous, mg/
dL
5.1 ± 1.1 5.8 ± 2.8 8.8 ± 3.3 7.6 ± 3.3 0.004 0.808 0.281
BUN, mg/dL 14.1 ± 2.4 14.7 ± 2.9 57.8 ± 12.2 54.4 ± 12.5 <0.001 0.650 0.513
PTH, pg/mL 190 ± 64 - 1499 ± 1117 994 ± 746 <0.001 0.201 NA
Data presented as mean and standard deviation. CKD, chronic kidney disease; NAC, N-acetylcysteine; BUN, blood urea nitrogen; PTH, parathyroid hormone.
�p< 0.05 versus control within disease.
https://doi.org/10.1371/journal.pone.0230379.t001
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measurable cortical porosity at the mid-diaphysis and levels were not affected by NAC treat-
ment (Table 2).
The effect of NAC on bone mechanics in CKD rats
The majority of mechanical properties, both structural and estimated material-level, exhibited
significant main effects of genotype, with CKD animals having inferior properties compared
to NL (Table 3). There was no main effect of NAC treatment nor an interaction between geno-
type and treatment.
Fig 1. The systemic marker of oxidative stress. Serum 8-OHdG (A) and TBPARS (B) in NL and CKD rats treated with or without NAC. Data presented as mean and
standard deviation with point plots of individual data. (n = 8–12 each group).
https://doi.org/10.1371/journal.pone.0230379.g001
Fig 2. The effect of CKD and NAC on bone architecture. Cortical, but not trabecular bone is affected by CKD with no effect of NAC on either compartment. A)
Proximal tibia trabecular bone was not significantly affected by NAC in either genotype. B) Cortical porosity was significantly higher in CKD animals while NAC did
not affect levels in either genotype. Data presented as mean and standard deviation with point plots of individual data. (n = 8–12 each group).
https://doi.org/10.1371/journal.pone.0230379.g002
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The effect of NAC on total bone AGE accumulation and skeletal collagen
cross-linking of femoral cortical bone
Total AGEs in femoral bone tissue from untreated CKD rats were significantly higher com-
pared to normal animals (Fig 3). There was a significant interaction for total bone AGE with
NAC-treated CKD rats having lower total bone AGE levels whereas NL rats treated with NAC
had no effect compared to untreated NL rats (Fig 3). Assessment of enzymatic collagen cross-
links and pentosidine by HPLC revealed that pyridinoline levels per unit collagen were signifi-
cantly lower in CKD animals compared to NL with no effect of NAC treatment (Table 4).
There was a significant interaction for pentosidine levels with NAC-treated NL animals having
lower skeletal pentosidine levels while CKD animals treated with NAC were not significantly
different compared to untreated controls (Table 4). Total AGE levels were negatively corre-
lated to a number of mechanical properties with r values of ~0.3 that were statistically signfii-
cant (Table 5).
Discussion
The systemic disruptions in mineral metabolism associated with chronic kidney disease are
profound and result in pathophysiological changes in numerous organ systems including
skeletal changes and calcification of arteries. Oxidative stress is common in many diseases
including chronic kidney disease [40]. Although the cause is often multi-factorial, reducing
oxidative stress represents a general approach to lessen the consequence of disease. In the pres-
ent study we demonstrated that NAC, an anti-oxidant, given beginning at 30 weeks of age
Table 2. Skeletal morphology of femoral mid-diaphysis.











Bone area, mm2 8.8 ± 0.8 9.1 ± 0.5 7.9 ± 1.0 7.5 ± 0.8 0.001 0.975 0.194
Cross-sectional moment of
inertia, mm4
9.9 ± 1.2 10.9 ± 1.3 9.4 ± 1.5 8.7 ± 1.1 0.003 0.701 0.071
Cortical thickness, mm 0.74 ± 0.04 0.77 ± 0.04 0.63 ± 0.09 0.61 ± 0.13 0.001 0.876 0.463
Data presented as mean and standard deviation. CKD, chronic kidney disease; NAC, N-acetylcysteine.
https://doi.org/10.1371/journal.pone.0230379.t002
Table 3. Mechanical properties of the femur mid-diaphysis.





interactionControl (n = 8) NAC (n = 7) Control (n = 12) NAC (n = 10)
Ultimate load, N 261 ± 19 252 ± 23 184 ± 45 183 ± 45 <0.001 0.667 0.739
Stiffness, N/mm 441 ± 36 415 ± 48 364 ± 42 347 ± 38 <0.001 0.125 0.755
Total displacement,
μm
846 ± 101 883 ± 128 662 ± 137 768 ± 187 0.003 0.207 0.380
Work to failure,
Nmm
129 ± 22 120 ± 24 70 ± 33 80 ± 39 <0.001 0.972 0.381
Ultimate stress, MPa 150 ± 17 140 ± 22 110 ± 32 114 ± 26 <0.001 0.706 0.419
Modulus, GPa 7.2 ± 0.8 6.5 ± 0.8 6.3 ± 1.0 6.4 ± 0.6 0.065 0.258 0.175
Total strain, μE 30371 ± 4115 31088 ± 4297 22967 ± 5242 26338 ± 6739 0.002 0.263 0.465
Toughness, MPa 2.59 ± 0.54 2.34 ± 0.55 1.45 ± 0.74 1.70 ± 0.84 0.001 0.989 0.297
Data presented as mean and standard deviation. CKD, chronic kidney disease; NAC, N-acetylcysteine.
https://doi.org/10.1371/journal.pone.0230379.t003
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(approximately 60–70% reduction in kidney function) for 5 weeks did not alter kidney func-
tion, assessed by BUN, or mineral metabolism in CKD rats. While NAC marginally lowered
serum levels of TBARS, a marker of lipid oxidation, it had no significant effect on serum
Fig 3. The effect of CKD and NAC on AGE accumulation. There was increased accumulation of AGE in femoral shaft from CKD rats compared to control rats
(Disease effect). There is no treatment effect overall but there is a significant interaction in which treatment with NAC reduced bone AGE accumulation in CKD rats but
not in NL rats. Data presented as mean and standard deviation with point plots of individual data (n = 8–12 each group). �p< 0.05 vs all other groups.
https://doi.org/10.1371/journal.pone.0230379.g003
Table 4. Skeletal collagen cross-linking of femoral cortical bone.







NAC (n = 9) Control
(n = 13)
NAC (n = 12)
Pyridinoline/mmol collagen 0.195 ± 0.03 0.20 ± 0.02 0.163 ± 0.02 0.168 ± 0.03 0.001 0.679 0.817
Deoxypyridinoline/mmol
collagen
0.131 ± 0.02 0.127 ± 0.02 0.119 ± 0.03 0.114 ± 0.03 0.138 0.595 0.976
Pentosidine/mmol collagen 70 ± 27 53 ± 10 � 59 ± 14 75 ± 31 0.444 0.925 0.023
Data presented as mean and standard deviation. CKD, chronic kidney disease; NAC, N-acetylcysteine.
�p< 0.05 versus control within disease.
https://doi.org/10.1371/journal.pone.0230379.t004
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8-OHDG, a marker of DNA oxidation. Furthermore, we found no end-organ effects of NAC
on the skeleton in CKD animals.
A major negative finding of this work is the absence of systemic oxidative stress elevations
in the CKD animals and modulation of levels in either treatment. We chose to assess oxidative
stress using 8-OHDG as it has shown to be elevated in our model of progressive chronic kid-
ney disease [41] and can be modulated by NAC [40]. Surprisingly, not only was there no effect
of disease, but there was no effect of NAC in either normal or disease conditions. Conversely,
there was a significant effect of NAC on lowering of TBARS, a common assessment of lipid
peroxidation. Previous work has shown that 7 weeks of NAC treatment (dosed orally at 150
mg/kg/day) reduced sodium fluoride-induced oxidative stress, as assessed by 8-OHDG [42].
Whether our conflicting results are due to different etiologies of oxidative stress, the need for
additional measures of oxidative stress, different dosing routes (or doses), or treatment time
are not clear. It is also unclear why there was no disease effect on oxidative stress given we
have seen this previously in our animals. This could be due to the heterogeneity in disease
severity we see across cohorts, although we observed many disease-induced changes that are
typical in our model, such as changes to BUN, PTH, and bone outcomes.
The influence of oxidative stress on bone has been studied predominantly in the context of
signaling bone cells. A lesser appreciated effect of oxidative stress is the effects it has on the
existing matrix. AGE accumulation in bone is associated with negative effects on bone
mechanical properties [7]. Their accumulation has been proposed to be responsible for the
bone fragility associated with diabetes, a result of high blood sugar and circulating AGE levels
(measured as HbA1c). Here we used a rat model of progressive CKD and demonstrated that
total bone AGE, but not pentosidine levels, are increased in CKD rats compared to NL. Previ-
ous studies in this same CKD model have documented both higher [12] and unchanged [38]
pentosidine levels in CKD animals. However, our current work documents that NAC lowered
total bone AGE levels, with no effect on bone pentosidine levels in in CKD animals. It is well-
known that pentosidine is just one of many AGEs within bone and that it’s concentration is
relatively low compared to some others [43] Given the link between AGEs and bone is in part
through their effects on mechanical properties [8][44][45], it is important to note that we
found there was no appreciable benefit of NAC on any mechanical properties, despite CKD
inducing many of the expected effects on reducing mechanical properties. This certainly points
to the concept that AGEs are not the whole story and that the metabolic disturbances in CKD
are having other tissue-level effects.

















-0.360 -0.335 -0.288 -0.368 -0.298 -0.353 -0.103 -0.347 -0.376 -0.223 -0.478
8-OHdG -0.388 -0.316 -0.364 -0.335 -0.357 -0.335 -0.177 -0.347 -0.025 -0.040 -0.134
PYD per
collagen
0.280 0.144 0.340 0.196 0.232 0.139 0.254 0.165 0.255 0.038 0.336
DPD per
collagen
0.324 0.324 0.194 0.297 0.361 0.339 0.202 0.328 0.248 0.243 0.290
PE per
collagen
-0.220 -0.168 -0.131 -0.148 -0.098 -0.155 0.110 -0.079 -0.325 -0.335 -0.272
Data presented as r values with red highlighted cells noting correlations with p < 0.05. AGE, advanced glycation end products; PYD, Pyridinoline; DPD,
Deoxypyridinoline; PE, Pentosidine; CSMI, cross-sectional moment of inertia
https://doi.org/10.1371/journal.pone.0230379.t005
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In addition to those discussed above, this work is limited in that assessments of the degree
of redox in the bone were not assessed. Therefore it is possible that changes (or lack of change)
in the serum does not reflect what is happening in the bone tissue.
In summary, NAC failed to alter the skeletal abnormality of our rat model of progressive
CKD. While it is plausible that higher doses or longer treatment may have had more benefit, it
is more likely that the pathophysiology of bone in CKD-MBD are multifactorial in etiology
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